Gastroenterology

Volume 165 / Issue 1 July 2023 www.gastrojournal.org

TABLE OF CONTENTS

Contents

ON THE COVER



BMPR2 *as a Predisposition for Colorectal Polyposis.* See article by Bonjoch, et al, page 162 for additional information.

COMMENTARIES

DIVERSITY, EQUITY, AND INCLUSION IN GI

MENTORING, EDUCATION, AND TRAINING CORNER

EDITORIALS

V Video CGH Related article in *CGH* Hot Papers From New Investigators

CME CME quiz E Editorial accompanies this article WWW Additional online content available COV Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2023 US subscription rates: individual, $848.00; student and resident, $323.00. Outside of the U.S. and possessions: individual, $1026.00; student and resident, $596.00; surface delivery, no additional charge; air mail delivery, add $78.00. Prices subject to change without notice.

GASTRO CURBSIDE CONSULT

ELECTRONIC *GASTRO* CURBSIDE CONSULT

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

ORIGINAL RESEARCH

Full Reports

Esophagus

Small Bowel

GI Cancer

88 **Single-Cell Profiling of Tumor Immune Microenvironment Reveals Immune Irresponsiveness in Gastric Signet-Ring Cell Carcinoma**

J. Chen, K. Liu, Y. Luo, M. Kang, J. Wang, G. Chen, J. Qi, W. Wu, B. Wang, Y. Han, L. Shi, K. Wang, X. Han, X. Ma, W. Liu, Y. Ding, L. Wang, H. Liang, L. Wang, and J. Chen

Gastric signet-ring cell adenocarcinoma is a rare gastric cancer subtype associated with poor patient survival. We provide the first molecular portrayal of immune components in this disease through integrative single-cell transcriptomic and proteomic profiling.

104 **Oncomicrobial Community Profiling Identifies Clinicomolecular and Prognostic Subtypes of Colorectal Cancer**

D. Mouradov, P. Greenfield, S. Li, E.-J. In, C. Storey, A. Sakthianandeswaren, P. Georgeson, D. D. Buchanan, R. L. Ward, N. J. Hawkins, I. Skinner, I. T. Jones, P. Gibbs, C. Ma, Y. J. Liew, K. Y. C. Fung, and O. M. Sieber

See editorial on page 25.

This study describes a gut bacteria-based classification system for bowel cancer that delineates 3 distinct subtypes that differ in tumor features and patient outcomes.

121 **Proteomic Profiling of Colorectal Adenomas Identifies a Predictive Risk Signature for Development of Metachronous Advanced Colorectal Neoplasia**

J. M. Bech, T. Terkelsen, A. S. Bartels, F. Coscia, S. Doll, S. Zhao, Z. Zhang, N. Brünner, J. Lindebjerg, G. I. Madsen, X. Fang, M. Mann, and J. M. Afonso Moreira

Colon polyps are mostly harmless but, over time, some can develop into colon cancer. This study showed that the protein content of polyps could predict events several years in advance.

133 **A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer**

H.-B. Yoo, J. W. Moon, H.-R. Kim, H. S. Lee, K. Miyabayashi, C. H. Park, S. Ge, A. Zhang, Y. K. Tae, Y. Sub, H.-W. Park, H. Y. Gee, F. Notta, D. A. Tuveson, S. Bang, M.-Y. Kim, and J.-S. Roe

TEAD2 expression is increased in basal-like pancreatic cancer cells and activates endothelial-like enhancers. Hence, inhibition of TEAD2 activity is sufficient to repress basal-like subtype differentiation and its associated phenotypes.

Inflammatory Bowel Disease

149 **Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial**

M. D. Kappelman, D. A. Wohl, H. H. Herfarth, A. M. Firestine, J. Adler, R. F. Ammoury, J. E. Aronow, D. M. Bass, J. A. Bass, K. Benkov, C. B. Tobi, M. E. Boccieri, B. M. Boyle, W. B. Brinkman, J. M. Cabera, K. Chun, R. B. Colletti, C. M. Dodds, J. M. Dorsey, D. R. Ebach, E. Entrena, C. B. Forrest, J. A. Galanko, J. E. Grunow, A. S. Gulati, A. Ivanova, T. W. Jester, J. L. Kaplan, S. Kugathasan, M. E. Kusek, I. H. Leibowitz, T. M. Linville, E. A. Lipstein, P. A. Margolis, P. Minar, Z. Molle-Rios, J. Moses, K. K. Olano, L. Osaba, P. J. Palomo, H. Pappa, K. T. Park, D. S. Pashankar, L. Pitch, M. Robinson, C. M. Samson, K. C. Sandberg, J. R. Schuchard, M. Seid, K. A. Shelly, S. J. Steiner, J. A. Strople, J. S. Sullivan, J. Tung, P. Wali, M. Zikry, M. Weinberger, S. A. Saeed, and A. Bousvaros

Tumor necrosis factor inhibitors, including infliximab and adalimumab, are a mainstay of pediatric Crohn's disease therapy; however, nonresponse and loss of response is common. Combination therapy with methotrexate may improve response. This randomized clinical trial compared tumor necrosis factor inhibitor combination therapy with methotrexate to tumor necrosis factor inhibitor alone. Combination therapy outperformed monotherapy for patients starting adalimumab, but not infliximab.

Colon

162 ***BMPR2* as a Novel Predisposition Gene for Hereditary Colorectal Polyposis**

L. Bonjoch, C. Fernandez-Rozadilla, M. Alvarez-Barona, A. Lopez-Novo, C. Herrera-Pariente, J. Amigo, L. Bujanda, D. Remedios, A. Dacal, J. Cubiella, F. Balaguer, F. Fernández-Bañares, A. Carracedo, R. Jover, S. Castellvi-Bel, and C. Ruiz-Ponte

Variants in the *BMPR2* gene affect molecular processes that could increase the risk of developing colonic polyposis and colorectal cancer.

Pancreas

Hepatobiliary

Endoscopy

Prevention and Early Detection

RESEARCH LETTERS

AGA SECTION

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

GASTRO DIGEST

CORRESPONDENCE